Готові списки джерел за темами / Head and neck squamous cell carcinomas (HNSCC)

Зміст

Статті в журналах
Дисертації
Книги
Частини книг
Тези доповідей конференцій
Звіти організацій

Добірка наукової літератури з теми "Head and neck squamous cell carcinomas (HNSCC)"

Автор: Grafiati

Опубліковано: 5 квітня 2025

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Head and neck squamous cell carcinomas (HNSCC)".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Head and neck squamous cell carcinomas (HNSCC)"

Rahman, Sadia, Sandra Kraljević Pavelić, and Elitza Markova-Car. "Circadian (De)regulation in Head and Neck Squamous Cell Carcinoma." International Journal of Molecular Sciences 20, no. 11 (May 30, 2019): 2662. http://dx.doi.org/10.3390/ijms20112662.

Повний текст джерела

Анотація:

Head and neck cancer encompass different malignancies that develop in and around the throat, larynx, nose, sinuses and mouth. Most head and neck cancers are squamous cell carcinomas (HNSCC) that arise in the flat squamous cells that makeup the thin layer of tissue on the surface of anatomical structures in the head and neck. Each year, HNSCC is diagnosed in more than 600,000 people worldwide, with about 50,000 new cases. HNSCC is considered extremely curable if detected early. But the problem remains in treatment of inoperable cases, residues or late stages. Circadian rhythm regulation has a big role in developing various carcinomas, and head and neck tumors are no exception. A number of studies have reported that alteration in clock gene expression is associated with several cancers, including HNSCC. Analyses on circadian clock genes and their association with HNSCC have shown that expression of PER1, PER2, PER3, CRY1, CRY2, CKIε, TIM, and BMAL1 are deregulated in HNSCC tissues. This review paper comprehensively presents data on deregulation of circadian genes in HNSCC and critically evaluates their potential diagnostics and prognostics role in this type of pathology.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ragin, C. C. R., F. Modugno, and S. M. Gollin. "The Epidemiology and Risk Factors of Head and Neck Cancer: a Focus on Human Papillomavirus." Journal of Dental Research 86, no. 2 (February 2007): 104–14. http://dx.doi.org/10.1177/154405910708600202.

Повний текст джерела

Анотація:

Head and neck cancer was the eighth leading cause of cancer death worldwide in 2000. Although the incidence of head and neck squamous cell carcinoma (HNSCC) in the United States is relatively low, survival is poor and has not improved for several decades. While tobacco and alcohol are the primary risk factors for HNSCC development, epidemiological studies report a strong association with human papillomavirus (HPV) in a subset of HNSCC. More than 95% of cervical squamous cell carcinomas are linked to persistent HPV infection; evidence demonstrates that HPV is a necessary carcinogen. Not all HPV-positive HNSCC express the viral oncogenes ( E6 and E7), which suggests that HPV may function as a carcinogen in a smaller proportion of HNSCC. This review presents our current understanding of the relationship between HPV and HNSCC, and describes future research directions that may lead to a better understanding of the involvement of HPV in head and neck cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

Meireles Da Costa, Nathalia, Fábio A. Mendes, Bruno Pontes, Luiz Eurico Nasciutti, Luis Felipe Ribeiro Pinto, and Antonio Palumbo Júnior. "Potential Therapeutic Significance of Laminin in Head and Neck Squamous Carcinomas." Cancers 13, no. 8 (April 15, 2021): 1890. http://dx.doi.org/10.3390/cancers13081890.

Повний текст джерела

Анотація:

Head and neck squamous cell carcinomas (HNSCC) are among the most common and lethal tumors worldwide, occurring mostly in oral cavity, pharynx, and larynx tissues. The squamous epithelia homeostasis is supported by the extracellular matrix (ECM), and alterations in this compartment are crucial for cancer development and progression. Laminin is a fundamental component of ECM, where it represents one of the main components of basement membrane (BM), and data supporting its contribution to HNSCC genesis and progression has been vastly explored in oral cavity squamous cell carcinoma. Laminin subtypes 111 (LN-111) and 332 (LN-332) are the main isoforms associated with malignant transformation, contributing to proliferation, adhesion, migration, invasion, and metastasis, due to its involvement in the regulation of several pathways associated with HNSCC carcinogenesis, including the activation of the EGFR/MAPK signaling pathway. Therefore, it draws attention to the possibility that laminin may represent a convergence point in HNSCC natural history, and an attractive potential therapeutic target for these tumors.

Стилі APA, Harvard, Vancouver, ISO та ін.

Norouzian, Marzieh, and Sima Balouchi-Anaraki. "Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma: A Focus on Tumor-Infiltrating Lymphocytes." Asian Pacific Journal of Cancer Biology 4, no. 2 (August 1, 2019): 19–26. http://dx.doi.org/10.31557/apjcb.2019.4.1.15-22.

Повний текст джерела

Анотація:

For more progress in head and neck squamous cell carcinoma (HNSCC) immuno-oncology, further understanding of interactions between tumor and immune system as well as factors in the tumor microenvironment is required. HNSCC is seriously infiltrated by lymphocytes but is known to be highly immunosuppressive. The aim of this review is to highlight the complexity of tumor microenvironment and tumor- immune cells interaction in the HNSCC, in order to improve understanding of tumorigenesis and disease progression in HNSCC patient and to provide valuable information about prognostic markers. The main goal of this review is to discuss the role of the tumor infiltrating lymphocytes in tumor progression, their cross-talk with other components of the tumor microenvironment as well as their roles in carcinogenesis, metastasis process, treatment, and prognosis in head and neck squamous cell carcinomas.

Стилі APA, Harvard, Vancouver, ISO та ін.

Lai, Sook Ling, May Leng Tan, Robert J. Hollows, Max Robinson, Maha Ibrahim, Sandra Margielewska, E. Kenneth Parkinson, et al. "Collagen Induces a More Proliferative, Migratory and Chemoresistant Phenotype in Head and Neck Cancer via DDR1." Cancers 11, no. 11 (November 9, 2019): 1766. http://dx.doi.org/10.3390/cancers11111766.

Повний текст джерела

Анотація:

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide and includes squamous cell carcinomas of the oropharynx and oral cavity. Patient prognosis has remained poor for decades and molecular targeted therapies are not in routine use. Here we showed that the overall expression of collagen subunit genes was higher in cancer-associated fibroblasts (CAFs) than normal fibroblasts. Focusing on collagen8A1 and collagen11A1, we showed that collagen is produced by both CAFs and tumour cells, indicating that HNSCCs are collagen-rich environments. We then focused on discoidin domain receptor 1 (DDR1), a collagen-activated receptor tyrosine kinase, and showed that it is over-expressed in HNSCC tissues. Further, we demonstrated that collagen promoted the proliferation and migration of HNSCC cells and attenuated the apoptotic response to cisplatin. Knockdown of DDR1 in HNSCC cells demonstrated that these tumour-promoting effects of collagen are mediated by DDR1. Our data suggest that specific inhibitors of DDR1 might provide novel therapeutic opportunities to treat HNSCC.

Стилі APA, Harvard, Vancouver, ISO та ін.

Davidson, Beverly L., Scott M. Graham, Eric A. Goebel, Joseph Zabner, and Jeffrey A. Kern. "Adenovirus-Mediated Gene Therapy for Head and Neck Squamous Cell Carcinomas." Annals of Otology, Rhinology & Laryngology 105, no. 7 (July 1996): 562–67. http://dx.doi.org/10.1177/000348949610500713.

Повний текст джерела

Анотація:

Advanced head and neck squamous cell carcinomas (HNSCCs) have a poor prognosis despite aggressive multimodal therapy. The goal of our study was to test the feasibility of gene transduction as a novel therapy for head and neck cancer. Three human HNSCC cell lines were transduced in vitro with a replication-deficient recombinant adenovirus containing the lacZ marker gene (Ad2/CMVßgal). Gene transduction efficiency was dependent on multiplicity of infection, duration of exposure to the virus, and viral concentration. Next, the HEp-2 cell line was transduced with an adenoviral vector (Ad.RSV tk) containing the herpes simplex virus thymidine kinase (HSV tk) gene, which, when expressed, sensitizes transduced cells to ganciclovir (GCV). Subsequent administration of GCV resulted in complete rumor cell killing. These results suggest that adenovirus-mediated transfer of KSV tk and administration of GCV has potential as a new therapy for HNSCC.

Стилі APA, Harvard, Vancouver, ISO та ін.

Chen, Huimin, Ke Hu, Ying Xie, Yucheng Qi, Wenjuan Li, Yaohui He, Shijie Fan, Wen Liu та Chenghua Li. "CDK1 Promotes Epithelial–Mesenchymal Transition and Migration of Head and Neck Squamous Carcinoma Cells by Repressing ∆Np63α-Mediated Transcriptional Regulation". International Journal of Molecular Sciences 23, № 13 (2 липня 2022): 7385. http://dx.doi.org/10.3390/ijms23137385.

Повний текст джерела

Анотація:

∆Np63α is a key transcription factor overexpressed in types of squamous cell carcinomas (SCCs), which represses epithelial–mesenchymal transition (EMT) and cell migration. In this study, we found that CDK1 phosphorylates ∆Np63α at the T123 site, impairing its affinity to the target promoters of its downstream genes and its regulation of them in turn. Database analysis revealed that CDK1 is overexpressed in head and neck squamous cell carcinomas (HNSCCs), especially the metastatic HNSCCs, and is negatively correlated with overall survival. We further found that CDK1 promotes the EMT and migration of HNSCC cells by inhibiting ∆Np63α. Altogether, our study identified CDK1 as a novel regulator of ΔNp63α, which can modulate EMT and cell migration in HNSCCs. Our findings will help to elucidate the migration mechanism of HNSCC cells.

Стилі APA, Harvard, Vancouver, ISO та ін.

Porcheri, Cristina, and Thimios A. Mitsiadis. "New Scenarios in Pharmacological Treatments of Head and Neck Squamous Cell Carcinomas." Cancers 13, no. 21 (November 3, 2021): 5515. http://dx.doi.org/10.3390/cancers13215515.

Повний текст джерела

Анотація:

Head and neck squamous cell carcinoma (HNSCC) is one of the most frequent types of cancer with a lethal outcome in half of the diagnosed cases. Mostly, HNSCC develops in the oral cavity, and its development is associated with tobacco and areca nut/betel quid usage, alcohol consumption, and HPV infection. Oral squamous cell carcinoma, as other head and neck cancers, presents a high degree of intratumor heterogeneity, which makes their treatment difficult, and directly correlates with drug resistance. Since the classical treatments for HNSCC oftentimes do not resolve the clinical picture, there is great need for novel therapeutic approaches, models for drug testing, and new drug delivery systems.

Стилі APA, Harvard, Vancouver, ISO та ін.

Bancu, Bancu, Richard Cowan, and Anshuman Chaturvedi. "PD-L1 TESTING AND IMMUNOTHERAPY SELECTION – EARLY LABORATORY EXPERIENCE AND ITS POTENTIAL ROLE IN HEAD AND NECK CANCER MANAGEMENT." Archive of Clinical Cases 8, no. 1 (March 31, 2021): 14–18. http://dx.doi.org/10.22551/2021.30.0801.10179.

Повний текст джерела

Анотація:

Anti-programmed cell death protein-1 (PD-1) therapy has been relatively recently approved in a defined context by NICE in adults in the management of recurrent and metastatic head and neck squamous cell carcinomas (HNSCC). In this context, companion diagnostic programmed cell death ligand-1 (PD-L1) testing, previously established at our center for lung and bladder tumors, was undertaken in a few head and neck cancer cases. The scope of this study was to audit the relevant PD-L1 data and integrate the findings in our current clinical practice, with a view to promote improved routine laboratory biomarkers in HNSCC. Histopathology reports documenting tumor type, PD-L1 result and type of clone/assay were included in this study. Over a 5-year period, PD-L1 testing was undertaken in 199 cancer cases, including 3 with head and neck squamous carcinoma with low focal positive staining. Immunotherapy treatment in HNSCC demonstrates a discreet but still significant improvement in the overall survival of PD-L1 positive subjects.

Стилі APA, Harvard, Vancouver, ISO та ін.

Baba, Yuh, Masato Fujii, Yutaka Tokumaru, and Yasumasa Kato. "Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer." Journal of Oncology 2012 (2012): 1–9. http://dx.doi.org/10.1155/2012/986725.

Повний текст джерела

Анотація:

Although EGFR is expressed at high levels in head and neck squamous cell carcinomas (HNSCCs) and mutations are extremely rare, monotherapy with EGFR inhibitors has shown limited success. The PI3kinase/Akt pathway is responsible for cellular survival, and inhibition of phosphatidylinositol (PI) synthesis has antiproliferative, anti-invasive, and antiangiogenesis effects on HNSCC. Molecular crosstalk has been observed between EGFR and IGF1R signaling through the PI3kinase/Akt pathway in HNSCC, as has molecular crosstalk between the NFκB and STAT3 signaling pathways. Therefore, the combination of an EGFR antagonist with an agent that inhibits the activation of both Akt and NFκB may overcome resistance to EGFR antagonists in HNSCC.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Дисертації з теми "Head and neck squamous cell carcinomas (HNSCC)"

OTON, GONZALEZ Lucia. "New biomarkers for human papillomavirus positive-head and neck squamous cell carcinomas." Doctoral thesis, Università degli studi di Ferrara, 2021. http://hdl.handle.net/11392/2478834.

Повний текст джерела

Анотація:

Il carcinoma a cellule squamose testa-collo (HNSCC) è una malattia eterogenea. La classificazione dei HNSCC si basa sulla posizione anatomica, lo stadio clinico, il fenotipo e la presenza del virus HPV, ed è importante per la scelta del trattamento appropriato. I tumori positivi all'HPV costituiscono un'entità diversa da quelli negativi all'HPV sia per il sito di insorgenza che la risposta al trattamento. Infatti, i tumori HPV-positivi di solito rispondono meglio ai trattamenti standard, e i pazienti presentano una sopravvivenza migliore. Tuttavia, un sottogruppo di questi pazienti presenta recidiva entro i primi due anni dalla diagnosi, e ridotta sopravvivenza. Perciò è necessaria la ricerca di nuovi marcatori che fungano da bersagli molecolari negli HNSCC, per poter aumentare la soppravivenza globale in tutti i gruppi. Diversi studi per comprendere le basi molecolari alla base della risposta differenziale nei pazienti HPV-positivi sono in corso, ma non è stata raggiunta una conclusione. Il problema principale è che non esistono linee guida standard per classificare i pazienti HPV-positivi. Molti studi indagano sul DNA dell'HPV, l'mRNA del virus e la sovraespressione di p16. Tuttavia, l'HPV potrebbe essere presente come infezione transitoria, l'espressione di p16 non è sempre osservata nei tumori HPV-positivi, e i livelli di mRNA dell'HPV potrebbere essere troppo bassi per essere rilevati. Pertanto, la rilevazione di marcatori classici non è sufficiente per stratificare i pazienti HNSCC-HPV positivi per la recidiva. In questo mio studio, ho verificato che la combinazione di marcatori classici con marcatori sierologici è risultata un forte indicatore prognostico. In particolare, per il carcinoma a cellule squamose dell'orofaringe (OPSCC) la presenza della oncoproteina E7 nel siero al momento della diagnosi era correlata alla recidiva della malattia e alla sopravvivenza globale. La ricerca di E7 nel siero può essere utile come procedura non invasiva per la stratificazione dei pazienti HPV-positivi e il follow-up, aiutando a identificare i pazienti a rischio di recidiva e fornendo uno strumento per la selezione dei pazienti candidati alla riduzione dei trattamenti chemio/radioterapici. Inoltre, poiché l'mRNA dell'HPV è necessario per promuovere la carcinogenesi e la long control region (LCR) del virus gioca un ruolo fondamentale nel controllo dell'espressione genica dell'HPV, abbiamo studiato come la variazione nucleotidica o la metilazione di questa regione influenzi l'espressione genica virale e la prognosi. Mentre la metilazione dell'LCR gioca un ruolo fondamentale nel controllo dell'mRNA virale, le variazioni della sequenza dell'HPV LCR resultano rilevanti per il legame con i fattori di trascrizione cellulari, influenzando l'espressione genica virale. Nello specifico, variazioni di sequenza all'interno del sito di legame del fattore di trascrizione YY1 erano correlate a una migliore sopravvivenza. Infine, la mia tesi discute un insieme di geni disregolati nell'HNSCC in correlazione ai sottogruppi di malattia e alla prognosi dei pazienti. Abbiamo trovato significative differenze per l'espressione genica di EGFR, p16, c-Jun e RARB tra i sottogruppi HPV-positivi e negativi; questi marcatori possono aiutare a creare un profilo di espressione al fine di stratificare i pazienti HNSCC alla diagnosi e selezionare il trattamento adeguato. Inoltre, diminuzioni nei livelli di IRF6 sono stati correlati a recidiva in pazienti HPV negativi. Nell’insieme i risultati presentati mostrano differenze molecolari tra tumori HPV-positivi e negativi, facendo luce su aspetti fondamentali della biologia dell'HPV e scarsamente studiati finora. Questi aspetti, sono ugualmente importanti per la sopravvivenza libera da progressione, e dovrebbero essere studiati in modo più approfondito in futuro come marcatori candidati per la stratificazione dei pazienti.
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease, and several attempts have been made to classify these tumors based on anatomic location, clinical stage and tumor phenotype. Once these characteristics are individualized, the appropriate treatment is chosen. For instance, HPV-positive HNSCCs have been defined as a different entity from HPV-negative based on its onset and treatment response. HPV-positive tumors usually respond better to standard treatment choices, while overall survival of these patients is improved. Still, a subset of these patients will present tumor recurrence within the first two years, presenting also reduced overall survival. There is a need to find new markers to serve as molecular targets in HNSCCs. Several studies are ongoing, in order to understand the molecular bases underneath this differential response in HPV-positive patients. Up to date, no common ground has been reached, the main issue being that there are no standard guidelines to classify HPV-positive patients. To improve stratification, many studies investigate HPV DNA, HPV mRNA and p16 overexpression. However, HPV might be present as a transient infection, and not active in the tumors, p16 expression is not always observed in HPV-positive tumors and HPV mRNA levels could be too low to be detected. In this study, similar to other studies, classical markers alone, were not sufficient to stratify HPV-positive HNSCC patients for disease recurrence. Nevertheless, the combination of classical markers with serological markers resulted a strong indicator of patient prognosis, particularly for oropharyngeal squamous cell carcinoma (OPSCC). HPV16 E7 oncoprotein presence in serum at the time of diagnosis correlated with disease recurrence and overall survival. Research for E7 oncoproteins in serum may be useful as a non-invasive procedure for patient stratification and follow-up, helping identify patients at risk for tumor recurrence, giving a tool for clinicians for candidate patients selection to de-escalate treatment. Furthermore, since HPV mRNA is necessary to promoter carcinogenesis and the long control region (LCR) of the virus plays a fundamental role in the control of HPV gene expression, we studied how variation or epigenetic control of this region could affect viral gene expression and patient prognosis. While methylation of the LCR plays a fundamental role in the control of HPV mRNA, the importance of regulation by other cellular transcription factors emerges, showing the importance HPV LCR sequence variations have for transcription factor binding and how they can greatly affect viral gene expression. Sequence variations within the YY1 transcription factor binding site, were correlated to improved patient survival, while patients carrying the reference sequence relapsed more frequently. Finally, my thesis discusses a set of genes dysregulated in HNSCC in correlation to the disease subgroups, and patient prognosis. Differences were significant for EGFR, p16, c-Jun and RARB gene expression between HPV-positive and negative subgroups; these markers may help create an expression profile in order to stratify HNSCC patients at diagnosis, and select the best treatment choice. Furthermore, diminished levels of IRF6 correlated to recurrence in HPV-negative patients. The findings presented in my thesis show molecular differences between HPV-positive and negative tumors and shed light on fundamental aspects of the HPV biology, that had been poorly studied in HNSCCs so far; first, the importance that HPV16 sequence has on the behavior of the virus and its pathogenic potential; and second, the presence of circulating viral oncoproteins in HPV-positive patients in serum. These aspects turned to be equally important related to patient’s progression free survival, and should be studied in more depth as candidate markers for patient stratification in the future.

Стилі APA, Harvard, Vancouver, ISO та ін.

Agwae, M. E. "The role of iRhom2 in the pathogenesis of head and neck squamous cell carcinomas (HNSCC)." Thesis, University of Liverpool, 2018. http://livrepository.liverpool.ac.uk/3022143/.

Повний текст джерела

Анотація:

It has been proposed that the Notch signalling pathway plays a key role in the pathogenesis of head and neck squamous cell carcinomas (HNSCC). It has also been shown that the sheddase, ADAM17, whose intracellular trafficking and subsequent maturation is dependent on iRhom2, is key in the activation of the Notch pathway at the cell membrane, leading to the release of an intracellular domain for downstream activities. This thesis investigates the levels and distribution of iRhom2 and ADAM17 in HNSCC, and functional changes resulting from up-regulation of iRhom2 in HNSCC cell lines. Immunoblotting, using protein samples extracted from fresh, snap-frozen tissues (68 HNSCC and 27 paired normal tissues), and probing for iRhom2 identified relatively high expression levels of this protein in 43/68 tumour samples compared to 5/27 normal samples (p < 0.05). Similar observations were obtained for ADAM17 expression, with high expression in 27/68 tumour samples compared to 4/27 normal samples (P < 0.05). A positive correlation was observed between levels of expressions of iRhom2 and ADAM17 in these tissues (though not statistically significant), but only iRhom2 expression correlated with patient survival (p < 0.05). Non-correlation of iRhom2 expression with other clinicopathological features was perhaps due to the relatively small number of samples investigated. Using a different cohort of HNSCC tissues, we also assessed levels of iRhom2 and ADAM17 and their intracellular distribution using tissue microarray (TMA) approach. Western blot results could not be corroborated with this methodology, given that most of the tissues stained negative for iRhom2, and 76/88 stained “highly positive” for ADAM17, with no observable specificity with ADAM17 staining pattern. Up-regulation of iRhom2 was achieved in the HNSCC cell lines, PE/CA-PJ15 and LIV37K; and in NOK (normal oral keratinocyte) cells and was, followed by shRNA knock-down of RHBDF2 (which codes for iRhom2). No observable differences were observed in the rate of cell replication when comparing wild-type, over-expressing and knock-down clones across each of the cell lines. However, a higher rate of cell migration was demonstrated in association with iRhom2 up-regulation, more in the HNSCC cell lines than the NOK. This higher rate of migration was shown to be reversed by the shRNA knock-down of RHBDF2, demonstrating that it is increased iRhom2 that is causative. Furthermore, a significant increase in the level of expression of mature ADAM17 was observed, following upregulation of iRhom2. iRhom2 and ADAM17 are both up-regulated in HNSCC, with up-regulation of iRhom2 associated with increased cell migration and decreased patient survival. Further experiments should aim to address whether it is the increased ADAM17 expression / activity and / or Notch activity that is the downstream effector of the observed effects. If will be important to expand the cohort of samples and cell lines used for this study to further validate the present findings, while also optimising some of the aspects that have not achieved significant results.

Стилі APA, Harvard, Vancouver, ISO та ін.

Bennett, Kristi Lynn. "Methylation in head and neck squamous cell carcinoma." Columbus, Ohio : Ohio State University, 2007. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=osu1194544327.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Wood, S. Matthew. "A Study of Head and Neck Squamous Cell Carcinoma Adhesion Mediated by Glycosphingolipids." Ohio University / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1314210756.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Haylock, Anna-Karin. "Targeting molecules for diagnostics of Head and Neck squamous cell carcinoma." Doctoral thesis, Uppsala universitet, Öron-, näs- och halssjukdomar, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-315210.

Повний текст джерела

Анотація:

To personalize treatment for cancer, correct staging of the primary tumor, nodal disease and metastatic disease is of essence. By targeting tumor specific receptors with radiolabeled antibodies, specificity and accuracy of imaging may be improved. Radio-immunodiagnostics can potentially detect small volume disease, occult metastasis and recurrent cancer in treated tissue. This thesis focuses on evaluation of radio-immunoconjugates directed towards CD44v6, which is a surface receptor overexpressed in many head and neck squamous cell carcinomas. At the outset, the monoclonal chimeric antibody cMab U36 and its cleavage products Fab’ and F(ab’)2 were labeled with 125I and assessed in vitro and in vivo (paper I). The best distribution pattern and tumor to organ ratio was achieved with F(ab’)2. Due to the immunological responses humans can develop towards chimeric antibodies, they are not optimal for clinical use, and subsequently fully human antibody fragments were developed. AbD15179, which is a monovalent fragment, was labeled with 111In and 125I and evaluated in vitro and in mice bearing CD44v6-expressing tumors. Tumor to organ ratios were improved compared to cMab U36 derived fragments, and 111In-AbD15179 displayed a more favorable distribution compared to 125I-AbD15179 (Paper II). A bivalent Fab-dHXL, AbD19384 derived from AbD15179, was then constructed and labeled with 125I and evaluated in cell- and biodistribution studies. Furthermore, an imaging study in a small animal PET was performed with 124I-AbD19384 (Paper III). Uptake in kidneys was reduced and liver uptake increased compared to AbD15179 reflecting the larger molecule. The high CD44v6 expressing tumor was clearly visualized with maximum uptake at 48 hours post injection.In paper IV human single chain fragments towards CD44v6v were selected, and the top candidates A11 and H12 were further evaluated in vitro and in vivo. Single chain fragments are small molecules exhibiting fast clearance and high affinity to the target. The study proved this by demonstrating superior tumor to blood ratios of radiolabeled A11 and H12 compared to previously studied molecules.

Стилі APA, Harvard, Vancouver, ISO та ін.

Lee, June Young. "The Role of Noxa/MCL-1 in Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment." VCU Scholars Compass, 2015. http://scholarscompass.vcu.edu/etd/3748.

Повний текст джерела

Анотація:

Head and neck cancer is the sixth leading type of cancer with 90 percent of head and neck cancer arising from squamous cell lining on the epithelium of the oral and nasal cavity, pharynx, and salivary gland. Even with tremendous achievements on chemotherapeutic drugs and therapies, the long-term prognosis of patients with advanced head and neck squamous cell carcinoma (HNSCC) has shown little improvement over the last three decades. Cisplatin is one of widely used chemotherapeutic drugs for multiple cancers, including head and neck cancer, but the prolonged use of this drug is limited by its toxicity and by the development of resistance. To overcome these major roadblocks to improved prognosis requires mechanism-based therapeutic strategies to maximize the antitumor effect of drugs while limiting their toxicities. Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of BCL-2 family-dependent mitochondrial apoptosis. DNA damage activates a tumor suppressor p53 to induce apoptosis. One of its functions is to induce the expression of several pro-apoptotic proteins such as Noxa, which binds to an anti-apoptotic BCL-2 family protein, MCL-1 (myeloid leukemia cell-1) to inactivate its pro-survival function and induce apoptosis. We examined Noxa expression and apoptosis induced by cisplatin in p53-wild-type HN30 and HN31, p53-truncated and inactive HN4 and HN12, and p53-deleted HN22 and HN8 HNSCC cell lines. We found that Noxa was induced in HN30 and HN31 cells and down-regulation of Noxa by shRNA (short-hairpin RNA) decreased apoptosis, indicating Noxa contribution to cisplatin-induced apoptosis. Interestingly, cisplatin treatment induced Noxa and apoptosis even in p53-deleted HN22 and HN8 cells, suggesting the existence of the p53-independent pathways for the induction of Noxa. Based on these observations, we hypothesized that modulation of Noxa/MCL-1 axis could mimic cisplatin-induced cell death. We found that Noxa overexpression induced cell death in all cell lines tested regardless of p53 status. This finding could be applicable as a potential therapeutic strategy to treat head and neck cancer.

Стилі APA, Harvard, Vancouver, ISO та ін.

Adams, Allie K. "Targeting the DEK oncogene in head and neck squamous cell carcinoma: functional and transcriptional consequences." University of Cincinnati / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1427882536.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Patel, Dhwani. "Regulation of EPS8 Dependent Pathways By Src in Head and Neck Squamous Cell Carcinoma." VCU Scholars Compass, 2015. http://scholarscompass.vcu.edu/etd/3810.

Повний текст джерела

Анотація:

Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that begins in the epithelial cells that line the mucosal surfaces of the head and neck, including the oral cavity, pharynx, larynx, paranasal sinuses, nasal cavity, and salivary glands. Head and neck cancer is the sixth most common type of cancer with a 5-year survival rate of 60% for all cases. Over the past few years, a subset of cells with stem-like properties, called cancer stem cells, are believed to have tumor-initiation capabilities and are responsible for maintaining on-going tumor growth. Previous data from our lab suggested that cells grown in suspension, called spheroids, may have stem cell like properties. We employed a model system where a primary HNSCC cell line, HN4, was used to set up spheroids. We found that expression of EPS8 and its downstream targets, FOXM1 and CXCL5, was increased in HN4 spheroids. In addition, we measured the expression of Nanog, as it is a transcription factor involved in the self-renewal of human embryonic stem cells. We also used a metastatic HNSCC cell line, HN12, to see how it compared to spheroids. We wanted to investigate the hypothesis that activation of Src potentiates EPS8 function to deregulate downstream signaling pathways. We used a small molecule tyrosine kinase inhibitor, Dasatinib, on HN4 spheroids and HN12 cells. We found that when Src is inhibited, EPS8 expression is decreased in HN4 spheroids and it also interferes with spheroid formation. The results of the current study were also able to show that the proliferation capability of HN12 cells is greatly diminished when treated with Dasatinib, due to G1 arrest in the cell cycle. When we measured for FOXM1, which is a cell cycle regulator, we found the levels were reduced in Dasatinib treated cells, preventing the cells from completing mitosis. With all of the data taken together, it suggests that Src does in fact play a role in regulating the downstream signaling pathways of EPS8, and its inhibition leads to the loss of cell proliferation. Additional studies need to be performed to discover whether Src inhibition will stop the proliferation of cancer stem cells, which are believed to be more resistant to cytotoxic therapies.

Стилі APA, Harvard, Vancouver, ISO та ін.

Maxim, Nicolas T. Mr. "Tumor-Specific Cell Death Induction by Noxa Overexpression for Head and Neck Squamous Cell Carcinoma (HNSCC) Treatment." VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4230.

Повний текст джерела

Анотація:

The primary focus of this research is the mechanisms of cell death in head and neck squamous cell carcinoma (HNSCC) treatment. These cancers typically originate in squamous cells that line the moist mucosal surfaces of head and neck. HNSCC is commonly treated with a platinum based agent, cisplatin. While the drug does offer strong antitumor effects, its prolonged use often results in tumor-acquired resistance, which limits treatment effectiveness. We have shown that cisplatin treatment induces the expression of a pro-apoptotic BCL-2 family member Noxa, which then initiates caspase- dependent apoptosis through its binding and sequestration of pro-survival protein MCL-1 for its inactivation. Without Noxa induction, cell death is significantly reduced when treating HNSCCs with cisplatin. The objectives of this study are (1) to determine the molecular mechanisms by which Noxa induces cell death in HNSCC cells; (2) to determine the molecular mechanisms of cisplatin-resistance in isogenic HNSCC cell lines. We observed an increase of apoptosis by ectopic expression of Noxa in all HNSCC cell lines tested, but not in immortalized human normal oral keratinocytes (NOK), suggesting that Noxa overexpression is sufficient to induce tumor-specific cell death. Noxa-induced cell death was mediated by BAX and BAK activation. BAK activation was mediated through Noxa binding to MCL-1, but not BCL-XL. Cisplatin- resistant cells induced less Noxa and apoptosis, supporting that Noxa induction is prerequisite for apoptosis induced by cisplatin. Taken together, Noxa induces tumor- specific cell death in HNSCC cells primarily through BAX and BAK activation, which suggests the therapeutic potential of this protein.

Стилі APA, Harvard, Vancouver, ISO та ін.

Chiriseri, Edina. "Human papilloma virus and oral cancers : sexual behaviour as a risk factor." Thesis, De Montfort University, 2017. http://hdl.handle.net/2086/16084.

Повний текст джерела

Анотація:

AIM & OBJECTIVES: Human papilloma virus (HPV) has been related to cervical infection, however, its part in Head and Neck Squamous Cell Carcinoma (HNSCC) is still debatable and is easy to refute. Suspicion of HPV causation is heightened when carcinomas arise in patients that are young and have never smoked. The present UK based study undertaken at Northampton NHS Trust endeavoured to determine the extent to which HPV is an entity in HNSCC in the UK. Furthermore, the study investigated whether sexual behaviour (as measured by sexual health clinic (SHC) attendance) is linked the acquisition of HPV associated HNSCC in young age groups. HNSCC incidences and sexual trends in the UK were collected from publicly available databases to identify if there were any changes at a national level in sexual behaviours and their influence on HNSCC in young age groups. MATERIALS & METHODS: PCR was used to evaluate the presence of HPV in biopsy samples from of 99 patients diagnosed with HNSCC at Northampton Hospital from 2006 to 2014. Patient demographics on age, sex, smoking, alcohol use and SHC attendance were also collected. All HPV PCR positive biopsies were further genotyped using an ABI 3130xl genetic analyser. Databases in the UK; including GLOBOCAN, NATSAL and PHE were searched for data on HNSCC prevalence, sexual behaviour trends and vaccine uptake. Multinomial regression explored the relationship between HPV positivity and sex, age, smoking, drinking, race and SHC attendance. RESULTS: PCR showed that 25.2% (25/99) of biopsies tested were positive for HPV and were all obtained from white participants. Most specimens (23, 92%) were high-risk (HR) HPV 16 positive with a mean age of 56 for HPV positivity and 72% of the cases 50-60 years old. Smokers were 11% in total (11/99) with most 88.9% participants (88/99) being non-smokers. HPV positivity was strongly linked with non-smoking history (p < 0.001); no alcohol abuse (p < 0.001); male gender (p < 0.001); young age less than 60 years (p < 0.001) and SHC attendance (p < 0.001). A Kruskal-Wallis post hoc test affirmed the impact of age on HPV positivity (p= < 0.05). GLOBOCAN and Cancer Research demonstrated a rising UK HNSCC pattern of over 200% for both sexes from 1975 to 2011. The three NATSAL surveys undertaken in 1990-1991, 1999-2001 and 2010-2012 demonstrated an overall increase in opposite and same sex partners. The UK average of individuals engaging in oral sex was in the younger age groups of between 16 and 54 with at least 70% of males and 63% females of that age engaging in oral sex. Finally, NASTAL 1, 2 and 3 surveys reported 20 vs 15; 25 vs 55; 55 vs 65 of males and females respectively with more than 10 sexual partners to have attended the SHC. The UK immunization take-up was over 90% countrywide. CONCLUSION: Few research studies have been conducted to date on HPV as a cause of HNSCC in the UK. The present research showed 25.2% of HNSCC to be caused by HPV, with the high risk (HR) genotype 16 (the leading cause of cervical cancer) accounting for 92% (23/25) of the cases. These outcomes affirmed the high prevalence of HR-HPV in HNSCC, with a rate of 25.2% similar to those reported previously. Routine HPV testing in those aged below 60 is therefore warranted. Smoking and drinking showed negative correlation; the young age of below 60 and attendance of the SHC for both sexes showed a positive correlation with HPV positive HNSCC. NATSAL data showed increased sexually risky behaviour coupled with attending the SHC in younger ages for both sexes. Increased sexually risky behaviour as shown in NASTAL surveys may be the reason why young age and SHC attendance is positively correlated with HPV HNSCC. The study highlights a conceivable relationship between HPV positive HNSCC in those under 60 years with no smoking history who attended the SHC. Smoking and drinking are known risks for HNSCC in those past 65 years of age; the negative association with HPV HNSCC in the young in the present research revealed smoking and drinking to have reduced association with HPV HNSCC. The reported HR-HPV positive HNSCC in young age groups inform future vaccination strategies and consequently decrease the quantity of HPV HNSCC's.

Стилі APA, Harvard, Vancouver, ISO та ін.

Більше джерел

Книги з теми "Head and neck squamous cell carcinomas (HNSCC)"

Kuo, Michael Jeo-Ming. Aberrations of chromosome arms 5q and 8p in squamous cell carcinomas of the head and neck. Birmingham: University of Birmingham, 1998.

Знайти повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Murphy, Barbara A., Lauren A. Zatarain, Anthony J. Cmelak, Steven Bayles, Ellie Dowling, Cheryl R. Billante, Sheila Ridner, et al. Palliative issues in the care of patients with cancer of the head and neck. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199656097.003.0145.

Повний текст джерела

Анотація:

Head and neck cancer (HNC) refers to tumours arising from the epithelial lining of the upper aerodigestive track, including the oral cavity, larynx, pharynx, paranasal sinuses, and salivary glands. There are 50,000 cases of HNC diagnosed annually within the United States. The majority of tumours (> 90%) are squamous cell carcinomas. Risk factors include tobacco, alcohol, and areca nuts; human papilloma virus (HPV) or Epstein-Barr virus; and mucosal irritation. Previously considered to be a disease of older adults, the epidemic of HPV-associated oropharyngeal cancers has led to a striking increase in HNC among middle-aged adults. Symptoms are usually present at the time of diagnosis and remain problematic through the terminal phase. For those patients who are cured, long-term biopsychosocial sequelae may persist for years. Thus, assessment and treatment of palliative issues is an intrinsic and vital component of care for the HNC patient.

Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Head and neck squamous cell carcinomas (HNSCC)"

Beyaert, Simon, Natasha Honoré, and Jean-Pascal Machiels. "Immune Checkpoint Inhibitors in the Curative Setting: Pre-clinical and Clinical Data." In Critical Issues in Head and Neck Oncology, 165–78. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23175-9_11.

Повний текст джерела

Анотація:

AbstractPembrolizumab and nivolumab, two monoclonal antibodies (mAbs) targeting programmed cell death protein-1 (PD-1), improve the overall survival of patients with inoperable recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). For curable HNSCC, the role of immunotherapy is under investigation. In this chapter, we briefly review the current use of immunotherapy with surgery or radio(chemo)therapy in the treatment of HNSCC with curative intent.

Стилі APA, Harvard, Vancouver, ISO та ін.

Chintakuntlawar, Ashish V., Hani Al-Halabi, and Aref Chehal. "Head and Neck Malignancies in the UAE." In Cancer Care in the United Arab Emirates, 535–44. Singapore: Springer Nature Singapore, 2024. http://dx.doi.org/10.1007/978-981-99-6794-0_31.

Повний текст джерела

Анотація:

AbstractHead and neck squamous cell carcinomas (HNSCCs) are one of the most common malignancies in the world. In this chapter, we discuss the incidence, pathogenesis, treatment, and future challenges in the management of HNSCC in the United Arab Emirates. Tobacco, alcohol, betel nuts, chewing tobacco, and chronic irritation and inflammation of the mucosal surfaces lead to these cancers. Human papillomavirus-associated oropharyngeal cancers (HPV-OPSCCs) occur at a lower rate compared to the western hemisphere. Due to the unique demographics of the UAE, HNSCC is an important cancer to focus on with regards to improving access to treatment, therapeutic paradigms, and research in both epidemiological and interventional clinical trials. In general, the treatment is aligned with international standards of care, with patients receiving expert surgical intervention, advanced radiotherapy treatments, and novel medical treatments, including immunotherapy. However, registry data, access to transoral robotic surgery, and interventional trials are severely lacking and need further collaboration within the oncologic community.

Стилі APA, Harvard, Vancouver, ISO та ін.

Rischin, Danny. "Biomarkers for Immune Modulatory Treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)." In Critical Issues in Head and Neck Oncology, 83–91. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_6.

Повний текст джерела

Анотація:

AbstractImmune checkpoint inhibitors have changed the standard of care for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). However, only a minority of patients respond, hence the search for predictive biomarkers. Potential predictive biomarkers for immune checkpoint inhibitors discussed in this chapter include (1) Immune checkpoint ligand expression e.g., PD-L1, (2) biomarkers of a T-cell inflamed tumour microenvironment (TME) such as gene expression profiles of activated T cells, (3) biomarkers of tumour neoepitope burden such as tumour mutation burden (TMB) and (4) multidimensional quantitative techniques. At present only PD-L1 expression has been shown to have clinical utility in head and neck cancer. It enriches for populations more likely to respond, but the false positive predictive value remains high. In the pivotal Keynote−048 trial that established a role for pembrolizumab (anti-PD1) monotherapy and pembrolizumab + chemotherapy as treatment options in first-line R/M HNSCC, primary endpoints included overall survival in defined subgroups based on PD-L1 expression. In this trial the combined positive score (CPS) was used which takes into account PD-L1 expression in tumour and immune cells. Based on this trial regulatory approvals for first-line pembrolizumab in R/M HNSCC require assessment of PD-L1 expression using the CPS. Finally we discuss emerging evidence that locoregionally advanced HPV-associated oropharyngeal cancers that have high expression of CD103 positive CD8 T cells have an excellent prognosis and features that suggest increased probability of responding to anti-PD1/PD-L1, raising the possibility of incorporating these immune therapies as part of a de-escalation trial strategy.

Стилі APA, Harvard, Vancouver, ISO та ін.

Borcoman, Edith, and Christophe Le Tourneau. "Novel Immune Oncology Targets Beyond PD-1/PD-L1 in Head and Neck Cancer." In Critical Issues in Head and Neck Oncology, 51–61. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23175-9_5.

Повний текст джерела

Анотація:

AbstractAnti-PD-1 immune checkpoint inhibitors have recently revolutionized the treatment of recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) patients, both in the first and second recurrent and metastatic settings. However, not all patients respond to PD-1 blockade, nor derive prolonged benefit from these immunotherapies, requiring further development of immune-oncology strategies beyond PD-1/PD-L1 inhibitors. There has been an important therapeutic development with the evaluation of many new immune checkpoints molecules and other type of immunomodulatory molecules, along with combinations of these new agents with PD-1/PD-L1 inhibitors, but very few of these strategies have shown significant anti-tumor activity as single agent in HNSCC patients, and further results are awaited from ongoing trials. All randomized trials assessing novel immune-oncology drugs in combination with an anti-PD1/PD-L1 agents have failed so far in HNSCC patients. Many other immune-oncology drugs are still in early clinical development and will hopefully improve HNSCC patient outcomes.

Стилі APA, Harvard, Vancouver, ISO та ін.

Moy, Jennifer, and Robert L. Ferris. "Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC)." In Molecular Determinants of Head and Neck Cancer, 365–96. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-78762-6_14.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

O’Leary, Ben. "Understanding Head and Neck Cancer Evolution to Guide Therapeutic Approaches." In Critical Issues in Head and Neck Oncology, 63–81. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23175-9_6.

Повний текст джерела

Анотація:

AbstractThe study of cancer evolution continues to deliver novel insights into the biology driving cancer. International consortia working on large genome sequencing initiatives have now provided an outline of the genomic landscape for many cancers. This vast resource of genomic data has also allowed the development of advanced computational tools revealing biology shaping genomic changes. Head and neck squamous cell carcinoma (HNSCC) is represented within the international consortia projects, though there remains only modest whole genome data and data from human papillomavirus-related cancers. Data for recurrent HNSCC and longitudinal data from patients treated with therapy are lacking and should be a priority for the community. This review will discuss the available resources and approaches for understanding HNSCC evolution, and consider how this might be applied to the clinical paradigm and used to develop the next generation of clinical trials.

Стилі APA, Harvard, Vancouver, ISO та ін.

Roden, Dylan F., Jennifer M. Johnson, Petr Szturz, Paolo Bossi, and Athanassios Argiris. "New and Promising Targeted Therapies in First and Second-Line Settings." In Critical Issues in Head and Neck Oncology, 277–96. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_18.

Повний текст джерела

Анотація:

AbstractDeeper understanding of the molecular pathogenesis of malignancies, including head and neck squamous cell carcinoma (HNSCC), has led to the investigation of several novel targeted therapies. These therapeutic approaches may eventually replace or complement existing treatment modalities, such as surgery, radiation therapy, and traditional cytotoxic chemotherapy. Epidermal growth factor receptor (EGFR) inhibitors, and specifically cetuximab, are as of now the only class of targeted agents, excluding immune checkpoint inhibitors, with approval in the treatment of HNSCC. Beyond EGFR inhibition, novel therapies under evaluation are directed against vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR), PI3K/AKT/mTOR pathway, cell cycle regulation (for example, cyclin dependent kinases 4 and 6), HRAS, DNA repair mechanisms, and others. Development of new therapies has to take into consideration the complexity of solid tumors and their heterogeneity. Multitargeted combination therapy approaches may be required in certain cases in order to maximize antitumor effect. Ways to individualize treatment using validated biomarkers are likely to improve outcomes. We review the most relevant molecular targets in HNSCC and provide updates on clinical trial data with promising new targeted agents.

Стилі APA, Harvard, Vancouver, ISO та ін.

Sanz-Garcia, Enrique, and Lillian L. Siu. "Targeting Molecular Residual Disease Using Novel Technologies and Clinical Trials Design in Head and Neck Squamous Cell Cancer." In Critical Issues in Head and Neck Oncology, 305–14. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-23175-9_18.

Повний текст джерела

Анотація:

AbstractHigh-risk human papillomavirus (HPV)-related and most cases of HPV-negative locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC) have substantial risks of relapse despite definitive therapy, and thus represent conditions of unmet clinical need. The ability now exists to detect molecular residual disease (MRD) in these patients post-definitive treatment such as surgery or (chemo)radiotherapy using novel and highly sensitive and specific technologies to measure cancer-derived circulating biomarkers. The positive and negative predictive values of these assays to forecast cancer recurrence, as well as the lead time of circulating tumor DNA (ctDNA) detection before clinical relapse, are relevant as these parameters rationalize the design of clinical trials for cancer interception in the MRD setting. Currently, there is evidence that interception in the MRD setting yields benefit in clinical outcome in some cancers, but such data do not yet exist in LA-HNSCC and will require prospective testing via clinical trials.

Стилі APA, Harvard, Vancouver, ISO та ін.

De Crevoisier, R. M. D., J. Bourhis, and F. M. D. Eschwéege. "Modified Fractionated Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) & Re-Irradiation in Recurrent Head and Neck Carcinomas." In Head and Neck Cancer, 199–212. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/0-306-48060-3_7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Tinhofer, Ingeborg. "The Role of Liquid Biopsies for Monitoring Disease Evolution." In Critical Issues in Head and Neck Oncology, 53–64. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_4.

Повний текст джерела

Анотація:

AbstractBody fluids of cancer patients have attracted increasing attention in biomedical research within the last 15 years since—as so-called liquid biopsies—they represent a non-invasive source of clinically exploitable biomarkers, including circulating tumor cells (CTCs) and cell-free tumor DNA (ctDNA). Assessment of CTCs in peripheral blood from solid cancer patients has proven useful for detection of subclinical disease which otherwise remains invisible for current staging techniques. Based on results from large cohort studies in breast and colon cancer, diagnostic tests for enumeration of CTCs have been developed which can be used for tumor staging, prognosis, and post-treatment surveillance. Circulating plasma DNA derived from Epstein–Barr or human papilloma viruses has been established as a sensitive and highly specific biomarker for early cancer detection and disease monitoring. More recently, first studies have been initiated for studying the diagnostic value of mutant variants in plasma-derived ctDNA for treatment selection, response assessment and early detection of treatment failure.Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) represents a malignancy associated with locoregionally advanced stage at presentation, dismal prognosis and little improvement in treatment outcome over the past decade, especially for patients with metastatic disease. HNSCC patients might therefore benefit from incorporation of liquid biopsy-based assays in clinical management. In the following chapters, I will summarize current evidence of the diagnostic value of liquid biopsies in HNSCC and give examples of potential clinical applications.

Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Head and neck squamous cell carcinomas (HNSCC)"

Jungbauer, F., S. Ludwig, N. Rotter, and A. Lammert. "Evaluation of the pretherapeutic staging in head-neck squamous cell carcinomas (HNSCC) – a retrospective study." In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1710967.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Clark, Cheryl A., Joyce Rong, and Cherie‐Ann O. Nathan. "Abstract A76: Curcumin inhibits head and neck squamous cell carcinoma (HNSCC) migration." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Dec 6–9, 2009; Houston, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1940-6207.prev-09-a76.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Theodoraki, MN, C. Brunner, and TK Hoffmann. "Modulation of the tumor microenvironment in Head and Neck Squamous Cell Carcinoma (HNSCC)." In Abstract- und Posterband – 90. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Digitalisierung in der HNO-Heilkunde. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1686084.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Li, X., Y. Sun, W. Wang, Q. Song, X. Lu, H. Li, L. Jia, and Y. Shen. "Managing distant metastasis from head and neck squamous cell carcinomas (HNSCC)- possible targets and potential treatment strategies." In Abstract- und Posterband – 90. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Digitalisierung in der HNO-Heilkunde. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1686021.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Altayeb, Yousra Bashir Fathalrhman, and Ecir Yılmaz. "Oral Squamous Cell Carcinoma (OSCC) Treatment by Magneti Nanoparticles (Hyperthermia Method): A Review." In 6th International Students Science Congress. Izmir International Guest Student Association, 2022. http://dx.doi.org/10.52460/issc.2022.020.

Повний текст джерела

Анотація:

Squamous cell carcinoma (SCC) is the most commonly diagnosed oral cancer. It is a type of head and neck squamous cell carcinoma (HNSCC) oral cancer affects more than 300,000 people in a year. Oral cancer is the sixth most common malignant cancer. The traditional methods of treatment were used through surgery, followed by chemotherapy, but these methods are not effective enough for the treatment, so treatment was focused on using magnetic nanoparticles. Magnetic nanoparticles demolish only the cancer cells directly without affecting healthy cells. They can also be used to increase the effectiveness of the other treatment methods. Iron oxide nanoparticles, maghemite (Fe2O3) and magnetite (Fe3O4) are widely used in the diagnosis and treatment of cancerous diseases. Iron oxides NPs have distinctive properties as they have good biodegradability, very low toxicity, modifiability, and ease of preparation. the method of hyperthermia is one of the effective methods in the treatment of cancer. Because cancer cells show greater sensitivity to high temperature compared to normal cells.

Стилі APA, Harvard, Vancouver, ISO та ін.

Chaudhary, Ritu, Xuefeng Wang, Biwei Cao, Nicholas T. Gimbrone, Robbert JC Slebos, and Christine H. Chung. "Abstract 1812: LncRNAs as prognostic biomarkers in head and neck squamous cell carcinoma (HNSCC)." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1812.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Zaheer, Saad, Sabaoon Zeb, and Faisal F. Khan. "Intelligent analysis of methylation data in Head and Neck Squamous Cell Carcinoma (HNSCC) interactomes." In 2021 International Conference on Artificial Intelligence (ICAI). IEEE, 2021. http://dx.doi.org/10.1109/icai52203.2021.9445265.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Bußmann, L., C. Betz, A. Münscher, M. Kriegs, K. Hoffer, AT Vu, S. Brand, C. Petersen, and K. Rothkamm. "Characterization of human head and neck squamous cell carcinoma (HNSCC) on a kinomic level." In Abstract- und Posterband – 90. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Digitalisierung in der HNO-Heilkunde. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1685974.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Rozek, Laura, Shama Virani, Emily Bellile, Jeremy Taylor, Maureen Sartor, Alisha Virani, Katie Rentschler, et al. "Abstract 3114: Soy isoflavones modulate global methylation in head and neck squamous cell carcinoma (HNSCC)." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3114.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Head and neck squamous cell carcinomas (HNSCC)"

Dżaman, Karolina, and Katarzyna Czerwaty. Extracellular Vesicle-Based Drug Delivery Systems for Head and Neck Squamous Cell Carcinoma: A Systematic Review. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2023. http://dx.doi.org/10.37766/inplasy2023.4.0021.

Повний текст джерела

Анотація:

Review question / Objective: This systematic review aims to identify studies investigating the membrane vesicle-based drug de-livery systems (DDS) for HNSCC and define the potential of extracellular vesicles (EVs) in the treatment of this disease according to the current state of knowledge. Condition being studied: Head and neck squamous cell carcinoma (HNSCC), which is ranked the sixth most common malignancy worldwide, originates in the epithelium of the oral and nasal cavities, pharynx, and larynx. The treatment of HNSCC remains a challenge and requires the involvement of a multidisciplinary team. Currently available methods of treatment, such as surgery, radiotherapy, and chemotherapy, cause significant dysfunctions and toxicity, which highlights the necessity to explore new therapeutic options. One-third of patients treated with intended curative surgery and adjuvant therapy experience local or regional recurrence and/or distant metastasis.

Стилі APA, Harvard, Vancouver, ISO та ін.

Dioguardi, Mario, Diego Sovereto, and Giuseppe Troiano. The Prognostic Role of miR-31 and miR-155 in HNSCC: Protocol. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, January 2022. http://dx.doi.org/10.37766/inplasy2022.1.0119.

Повний текст джерела

Анотація:

Review question / Objective: the PICO question was formulated , in which the following points are identified: Participants (patients with HNSCC), Intervention (altered expression of miR-31 and miR-155 in HNSCC), Control (patients with HNSCC who have low expression of miR-31 and miR-155), Outcome (difference in prognosis of survival among patients with low and high miR-31 and miR-155 expression in HNSCC The PICO question therefore is as follows: Is there a difference in OS (overall Survival) between HNSCC patients with high miR-31 and miR-155 expression versus those with low expression? Condition being studied: Head and Neck Squamous Cell Carcinoma (HNSCC), altered expression of miR-31 and miR-155 tissue.

Стилі APA, Harvard, Vancouver, ISO та ін.

Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!